Author: Sofia Dahlberg

NorthX Biologics, a leading Nordic biopharmaceutical Contract, Development, and Manufacturing Organization (CDMO), is pleased to announce a significant growth investment from Signet Healthcare Partners (Signet), a U.S.-based healthcare private equity firm with deep expertise in pharmaceutical services. This strategic partnership will enable NorthX Biologics to accelerate its expansion plans, including enhancing facilities, broading service lines, and extending U.S. commercial reach.

NorthX Biologics provides a wide range of complex biologics manufacturing services, including recombinant proteins, viral vaccines and cell therapies. It serves a global customer base of biopharmaceutical and biotech companies, from early development through commercial GMP manufacturing.

The investment was made through a new issue of shares. Following the transaction, James Gale, Managing Director at Signet Healthcare Partners, will join the NorthX Biologics Board of Directors.

“We are delighted to welcome Signet Healthcare Partners as a shareholder. With their significant experience in pharma services, they are an excellent complement to NorthX Biologics and are well positioned to support our journey” said Janet Hoogstraate, Chief Executive Officer of NorthX Biologics.

“With Signet Healthcare Partners, we gain another strong owner who brings extensive experience in developing fast-growing biopharmaceutical companies. I look forward to welcoming James to the board and working together with Signet to continue the global expansion of NorthX Biologics,” added Thomas Eldered, Chairman of NorthX Biologics and Flerie.

“We are excited to invest in NorthX Biologics to support its ambitious growth strategy. NorthX Biologics’ differentiated capabilities across microbial and mammalian manufacturing systems, nucleic acids, advanced therapies and aseptic fill-finish are a strong match with the evolving needs of the global biopharma market. Together with Flerie, as a significant shareholder in NorthX Biologics, we look forward to helping accelerate NorthX Biologics commercial strategy while supporting its broader global vision,” said James Gale, Managing Director at Signet Healthcare Partners.

Flerie remains the majority shareholder following the transaction. Terms were not disclosed. Setterwalls served as legal advisor to NorthX Biologics. Advokatfirman Delphi and Sheppard, Mullin, Richter & Hampton served as legal advisors to Signet.

About Flerie
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com.

About Signet Healthcare Partners
Signet Healthcare Partners is a leading provider of growth capital to innovative healthcare companies, with a focus on the pharmaceutical and medical device sectors. With over 25 years of experience, Signet has raised cumulative capital commitments exceeding $600 million and invested in over 60 companies. The firm works closely with its portfolio companies to drive value and accelerate growth. For more information, visit www.signethealthcarepartners.com.

Biopharmaceutical contract development and manufacturing organization (CDMO) NorthX Biologics is pleased to announce the appointment of Johanna Magnusson as Chief Operating Officer.

With over two decades of leadership experience in life sciences operations, production, and quality management, Johanna is a powerful addition to the NorthX Biologics team. She most recently served as Global Operations Director and Site Leader at Cavidi AB, where she was instrumental in driving strategic transformation and introducing innovative technologies to the diagnostics and pharmaceutical sectors. Prior to that, Johanna held several senior leadership roles at Cytiva (formerly GE Healthcare) in Uppsala, Sweden, where she led major production initiatives and implemented LEAN and Six Sigma methodologies to significantly enhance productivity and operational performance.

Johanna holds a Master of Science in Chemical Engineering from Umeå University, Sweden, and is a certified Six Sigma Black Belt as well as a certified Board Member through Styrelseakademin. With her international experience, she brings a global mindset to her leadership approach.

Janet Hoogstraate, CEO NorthX Biologics commented: “We are delighted to welcome Johanna. Her extensive experience in operational leadership and process excellence will be a tremendous asset as we continue to scale and expand our capabilities. Johanna’s strategic insight and collaborative approach align perfectly with our mission to deliver world-class services to our clients.”

Johanna added: “I’m excited to join NorthX Biologics at such a dynamic point in its journey. The company’s end-to-end portfolio — from microbial and mammalian recombinant proteins to viral vectors, mRNA, plasmids, cell therapy, and extracellular vesicles — is truly impressive. I look forward to working with the team to help our clients bring transformative therapies to patients around the world.” This strategic appointment reinforces NorthX Biologics’ commitment to operational excellence and innovation, as it continues to deliver cutting-edge solutions for the global biopharmaceutical industry.

NorthX Biologics, a leading biopharmaceutical CDMO, has been officially accredited by the French Ministry of Higher Education and Research for the Crédit d’Impôt Recherche (CIR) program for the years 2025-2026.

The Crédit d’Impôt Recherche (CIR) is a French tax incentive designed to support research and development (R&D) activities within the country. This program allows eligible companies to deduct qualified R&D expenses from their corporate taxes under specific conditions, fostering innovation and scientific advancement.

This accreditation reinforces NorthX Biologics’ role as a trusted innovation partner for France’s pharmaceutical and biotech sectors, providing cost-effective access to advanced R&D services in microbial and mammalian systems.

“Receiving CIR accreditation is a testament to our expertise and the high-quality R&D services we provide. The accreditation underscores our reputation as an innovation driver in the development and manufacture of biopharmaceuticals. We remain committed to enabling R&D-driven organizations in achieving their scientific goals” said Janet Hoogstraate, CEO of NorthX Biologics.

About the CIR Research Tax Credit
The research tax credit (Crédit d’Impôt Recherche, CIR) is a central political tool for the benefit of research and innovation. By promoting R&D, this tax relief can increase the competitiveness of companies. It is adapted to the needs of small and midsize enterprises, in particular. Crédit d’impôt recherche (CIR) | Entreprendre.Service-Public.fr

Read the French version here.